Pediatric Hematology/Oncology

Drug Toxicity

Questions discussed in this category

What, if any, cardioprotective measures beyond dexrazoxane may be used to minimize cardiac risk during or after chemo- or radio-therapy?

Are there other measures, pharmocologic or adjunctive, that can be used or are under investigation to mitigate cardiotoxicity related to chemo- or rad...

2 Answers available

Papers discussed in this category

Eur Heart J, 2022 Nov 01

2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS).

JACC. Heart failure, 2022 Jun 08

Sodium-Glucose Co-Transporter-2 Inhibitors and Cardiac Outcomes Among Patients Treated With Anthracyclines.

JAMA, 2023 Aug 8

Atorvastatin for Anthracycline-Associated Cardiac Dysfunction: The STOP-CA Randomized Clinical Trial.

Cardio-oncology (London, England), 2021 Sep 27

Rationale and design of the PRevention of cArdiac Dysfunction during Adjuvant breast cancer therapy (PRADA II) trial: a randomized, placebo-controlled, multicenter trial.

JACC. CardioOncology, 2023 Jun 20

Cardioprotection in Patients at High Risk of Anthracycline-Induced Cardiotoxicity: Primer.

Pediatric Hematology/Oncology

Drug Toxicity

Questions discussed in this category

Papers discussed in this category

Related Topics in Pediatric Hematology/Oncology